Alterity Therapeutics Completes Enrolment in ATH434-201 Phas

– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants globally – MELBOURNE, Australia...

Related Keywords

New Zealand , United States , California , Melbourne , Victoria , Australia , San Francisco , David Stamler , Remy Bernarda , Hannah Howlett , Alterity Therapeutics , European Commission , Securities Exchange , Nasdaq , System Atrophy National Institute Of Neurological Disorders , Chief Executive Officer , Multiple System Atrophy , System Atrophy , National Institute , Neurological Disorders , Multiple System , Media Contacts , Securities Act , Securities Exchange Act , Annual Report , Markets ,